During pathogenic influenza virus infection, robust cytokine production (cytokine storm), excessive inflammatory infiltrates, and virus-induced tissue destruction all contribute to morbidity and mortality. Earlier we reported that modulation of sphingosine-1-phosphate-1 receptor (S1P 1 R) signaling provided a chemically tractable approach for the effective blunting of cytokine storm, leading to the improvement of clinical and survival outcomes. Here, we show that S1P 1 R agonist treatment suppresses global cytokine amplification. Importantly, S1P 1 R agonist treatment was able to blunt cytokine/chemokine production and innate immune cell recruitment in the lung independently of endosomal and cytosolic innate sensing pathways. S1P 1 R signaling suppression of cytokine amplification was independent of multiple innate signaling adaptor pathways for myeloid differentiation primary response gene 88 (MyD88) and IFN-β promoter stimulator-1 signaling, indicating a common pathway inhibition of cytokine storm. We identify the MyD88 adaptor molecule as responsible for the majority of cytokine amplification observed following influenza virus challenge.
During pathogenic influenza virus infection, robust cytokine production (cytokine storm), excessive inflammatory infiltrates, and virus-induced tissue destruction all contribute to morbidity and mortality. Earlier we reported that modulation of sphingosine-1-phosphate-1 receptor (S1P 1 R) signaling provided a chemically tractable approach for the effective blunting of cytokine storm, leading to the improvement of clinical and survival outcomes. Here, we show that S1P 1 R agonist treatment suppresses global cytokine amplification. Importantly, S1P 1 R agonist treatment was able to blunt cytokine/chemokine production and innate immune cell recruitment in the lung independently of endosomal and cytosolic innate sensing pathways. S1P 1 R signaling suppression of cytokine amplification was independent of multiple innate signaling adaptor pathways for myeloid differentiation primary response gene 88 (MyD88) and IFN-β promoter stimulator-1 signaling, indicating a common pathway inhibition of cytokine storm. We identify the MyD88 adaptor molecule as responsible for the majority of cytokine amplification observed following influenza virus challenge.
pathology | pulmonary O verabundant innate immune responses correlate with increased morbidity and mortality during multiple pathogenic respiratory viral infections (1) (2) (3) (4) (5) . When studying human pandemic H1N1/2009 influenza virus in mice and ferrets, we found direct evidence that cytokine storm was chemically tractable using a sphingosine-1-phosphate receptor-1 (S1P 1 R) selective agonists. S1P 1 R agonist therapy suppressed innate immune cell recruitment, cytokine-chemokine production, and improved survival without altering viral clearance, indicating that cytokine storm was causative to disease pathogenesis and that S1P therapy could suppress detrimental innate immune responses without hindering virus control (6, 7) . The identification that S1P 1 R agonists suppress detrimental innate immune responses without hindering virus control indicates that S1P 1 R probes may serve as both viable drug leads to curb influenza virus morbidity and mortality, and as research tools to identify additional cellular signaling pathways that can be targeted to improve clinical outcomes during respiratory viral infection.
To generate a molecular understanding how S1P 1 R agonist therapy effectively blunts pathological innate inflammatory responses, we systematically assessed the role various innate signaling pathways play in S1P 1 R-mediated suppression of inflammation following influenza virus infection. Using an S1P 1 R selective agonist synergistically with genetic and biochemical tools, we reveal that S1P 1 R signaling effectively suppressed global cytokine amplification at a point that converged downstream of multiple innate signaling pathways. We reveal that S1P 1 R signaling can suppress innate cellular recruitment and cytokine amplification downstream of both endosome and cytosolic innate sensing pathways. Moreover, we identify myeloid differentiation primary response gene 88 (MyD88) as the predominant signaling molecule required for innate immune cell recruitment and cytokine/chemokine production following influenza virus infection. This study indicates that S1P 1 R agonist efficacy during influenza virus infections occurs through its capacity for common pathway inhibition downstream of multiple innate pathogen-sensing molecules of cytokine amplification.
Results

S1P 1 R Agonism Blunts Innate Cellular and Cytokine Responses
Independently of Toll-Like Receptor 3 or -7 Signaling. Multiple pattern recognition receptors have been documented to sense influenza virus infection and elicit innate immune responses, including Toll-like receptors (TLR3 and -7), cytosolic receptors (retinoic acid-inducible gene, RIG-I) and nucleotide binding domain and leucine-rich repeat containing proteins (NLRs, NLRP3) (8) . We asked whether recognition of influenza virus generated double-stranded (ds)RNA (TLR3) or single-strand (ss)RNA (TLR7) was required for S1P 1 R-mediated inhibition of cytokine and innate cellular responses. To address this question, we infected TLR3-or TLR7-deficient mice with the H1N1 WSN strain of influenza virus and treated infected mice with either vehicle or the S1P 1 R agonist, CYM5442. Influenza virus infection in TLR3-deficient mice resulted in slightly elevated production of IFN-α, IL-6, chemokine (C-C) ligand (CCL)2, and CCL5, along with a significant increase in the production of IFN-γ compared with wild-type controls (Fig. 1A) . Moreover, treatment of TLR3-deficient mice with S1P 1 R agonist following influenza virus infection resulted in significant reduction of IFN-α as well as all cytokines and chemokines analyzed (Fig. 1A) . In contrast to TLR3-deficient mice, influenza virus infection of TLR7-deficient mice resulted in significantly reduced levels of IFN-α in the bronchoalveolar lavage fluid (BALF) 48 h postinfection compared with wild-type controls (Fig. 1B) . Interestingly, similar levels of IL-6, CCL2, CCL5, and IFN-γ were detected in the BALF of TLR7-deficient mice compared with wild-type controls
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Author contributions: J.R.T., K.B.W., H.R., and M.B.A.O. designed research; J.R.T., K.B.W., and S.R. performed research; J.R.T., H.R., and M.B.A.O. analyzed data; and J.R.T. and M.B.A.O. wrote the paper. (Fig. 1B) . Furthermore, treatment of influenza virus-infected mice with S1P 1 R agonist resulted in a significant >twofold suppression of IFN-α compared with vehicle-treated controls (Fig. 1B, Inset) as well as significant suppression of all cytokine and chemokines measured (Fig. 1B) , collectively demonstrating that S1P 1 R agonism can suppress innate cytokine and chemokine production independently of TLR3 or -7 signaling.
In addition to suppressing cytokine and chemokine production, we demonstrated that S1P 1 R agonist therapy also inhibits innate immune cell activation and recruitment into the lung following influenza virus infection (6, 7, 9) . Thus, we asked what role, if any, TLR3 and -7 signaling played in innate immune cell activation and recruitment into the lung. We observed similar numbers of activated macrophages/monocytes and natural killer cells (NK cells) in the lung 48 h postinfection in both TLR3 and TLR7-deficient mice compared with wild-type controls ( Fig. 1 C and E). Moreover, S1P 1 R agonist therapy reduced numbers of activated macrophages/monocytes and NK cells in the lung 48 h postinfection in both TLR3-and TLR7-deficient mice ( Fig. 1 C and E). We also observed reduced expression of the CD69 activation marker on macrophages/monocytes and NK cells following S1P 1 R agonist treatment in both TLR3-and TLR7-deficient mice following influenza virus infection (Fig. S1 ). S1P 1 R agonist treatment following influenza virus infection reduced numbers of neutrophils in the lung in both TLR3-and TLR7-deficient mice ( Fig. 1 D and F) . These data indicate that S1P 1 R agonist therapy is efficacious in reducing innate cytokine/ chemokine production and immune cell recruitment independently of either TLR3 or TLR7 signaling. ) signaling. The 3d mutant mice respond to endosome TLR ligands (TLR3, -7, and -9) (10). Conversely, mitochondrial IPS-1 is the central adaptor protein for RIG-I signaling and IPS-1 −/− mice are unable to signal through the RIG-I or melanoma differentiation-associated-5 sensors (11). We infected either 3d or IPS-1 −/− mice with influenza virus, treated infected mice with either vehicle or S1P 1 R agonist, and measured innate immune responses following infection. Similar to TLR7-deficient mice, infection of 3d mice resulted in significant reduction in the levels of IFN-α in the BALF 48 h following infection compared with wild-type controls ( Fig. 2A) . Reductions in IL-6 and IFN-γ levels were also observed in 3d mice compared with controls ( Fig. 2A) . Despite reduced cytokine/chemokine production in 3d mice following influenza virus infection, significant levels of IFN-α, IL-6, CCL2, CCL5, and IFN-γ were produced ( Fig. 2A) , suggesting that additional innate signaling pathways (likely RIG-I and NLRP3) are able to elicit cytokine/ chemokine responses in the absence of endosome TLR signaling. Importantly, S1P 1 R agonist therapy further suppressed IFN-α production ( Fig. 2A, Inset) as well as all other cytokines/chemokines analyzed in 3d mice ( Fig. 2A ), indicating that S1P 1 R agonism blunts cytokine/chemokine production independently of endosomal TLR signaling. Alternatively, influenza virus infection in IPS-1 −/− mice resulted in reduced IFN-α and IFN-γ levels in BALF despite similar levels of IL-6, CCL2, and CCL5 compared with wild-type controls (Fig. 2B ). Similar to 3d mice, IPS-1 −/− mice produced significant levels of all cytokines and chemokines analyzed 48 h postinfection (Fig. 2B ), suggesting that endosomal TLR and NLRP3 signaling can compensate for the absence of IPS-1. Despite significant production of cytokines and chemokines in IPS-1 −/− mice following influenza virus infection, S1P 1 R agonist treatment suppressed all cytokines and chemokines produced (Fig. 2B) . We also analyzed innate cellular recruitment in 3d and IPS −/− mice following influenza virus infection and treatment with S1P 1 R agonist. Despite reductions in IFN-α and multiple cytokines/chemokines in 3d mice, no significant differences in recruitment of innate immune cells, including macrophages/ monocytes, neutrophils, and NK cells, occurred compared with wild-type controls (Fig. 2C ). Moreover, S1P 1 R agonist treatment reduced recruitment of macrophages/monocytes and neutrophils into the lung in 3d mice following influenza virus infection (Fig.  2C) . We observed reduced expression of the early activation marker CD69 on macrophages/monocytes and NK cells in 3d mice compared with WT controls (Fig. S2 ). Similar to 3d mice, we observed no difference in activation or recruitment of activated macrophages or neutrophils to the infected lung comparing wild-type and IPS-1 −/− mice following influenza virus infection ( Fig. 2 D and E) . S1P 1 R agonist treatment inhibited the total numbers of macrophages/monocytes (Fig. 2E ) and neutrophils (Fig. 2F ) in the lungs of IPS-1 −/− mice. The cytokine and cellular data above demonstrate that S1P 1 R agonist therapy inhibits early influenza virus innate inflammatory responses independent of endosomal or cytosolic signaling, suggesting that S1P 1 R agonist acts downstream of multiple innate signaling pathways.
IL-1R Signaling Is Required for Cytokine Amplification and Innate
Cellular Recruitment Following Influenza Virus Infection. In addition to endosome (TLR3, -7) and cytosolic (RIG-I) sensors, influenza virus infected cells can activate the NLRP3 inflammasome (12, 13) . The end result of inflammasome activation is the cleavage of pro-IL-1 and pro-IL-18 to active proteins. In turn, secreted IL-1 can signal through the IL-1R to induce inflammatory gene production through MyD88 signaling. Signaling of IL-1 through the IL-1R contributes to both host protection and immune pathology following influenza virus infection. We asked what role IL-1-IL-1R signaling played in early cytokine amplification during influenza virus infection. IL-1R-deficient mice made significantly less IFN-α, as well as IL-6, CCL5, CXCL10, and IFN-γ compared with IL-1R-sufficient mice (Fig. 3A) . We observed significant reduction in the numbers of activated macrophages/monocytes and NK cells (Fig. S3A) , as well as expression levels of CD69 on these cellular populations in the lung in IL-1R-deficient mice (Fig. S3B) . Furthermore, we detected significant reductions in neutrophils in IL-1R-deficient compared with IL-1R-sufficient lungs (Fig. S3C ), which correlates with previous studies demonstrating reduced neutrophil recruitment in IL-1R-deficient mice following influenza virus infection (14) . Collectively, our results demonstrate that IL-1R signaling contributes to early cytokine amplification following influenza virus challenge and may be a mechanism by which S1P 1 R signaling blunts cytokine storm.
Endothelial cells (EC) are activated by IL-1α and -β and TNF-α to induce chemokine production and adhesion molecule expression on the endothelium of inflamed tissues facilitating recruitment of inflammatory immune cells. We asked whether IL-1R signaling was required on hematopoietic or nonhematopoeitic cells in the lung. To address this question, we made bone-marrow chimeras between IL-1R +/+ and IL-1R +/+ or IL-1R −/− bone marrow cells (Fig. 3B) . Recruitment of activated macrophages and NK cells, as well as expression levels of the activation marker CD69, was also reduced in mice deficient in IL-1R on nonhematopoeitic cells (Fig.  S3 D and E) . These results suggest that IL-1R signaling (likely through MyD88) is essential on nonhematopietic cells for cytokine amplification and recruitment of activate leukocytes following influenza virus infection. Moreover, pulmonary ECs express S1P 1 R and S1P 1 R signaling may suppress chemokine production from pulmonary ECs following IL-1 signaling, which may explain the S1P 1 R-mediated suppression of innate immune cell recruitment following influenza virus infection.
Finally, we asked whether S1P 1 R agonist treatment could further suppress cytokine/chemokine production in IL-1R-deficient mice. In agreement with our previous results, IL-1R-deficient mice produced significantly less IFN-α, CCL2, and IL-6 compared with IL-1R-sufficient mice following influenza virus infection (Fig. 3C) , whereas only modest reductions in TNF-α, CCL5, and IFN-γ were observed when comparing IL-1R-sufficient to IL-1R-deficient mice (Fig. 3C) . We observed significant suppression of CCL5, IFN-γ, and TNF-α in IL-1R-deficient mice upon treatment with S1P 1 R agonist following influenza virus infection (Fig. 3C) , as well as reduction of IFN-α, CCL2, and IL-6, although the reduction did not reach statistical significance (Fig. 3C) . Whereas the frequency and total numbers of activated macrophages were reduced in the lung of IL-1R-deficient mice, S1P 1 R agonism was able to further suppress the recruitment of activated macrophages (Fig. S3 F and G) . However, although we observed reduced numbers of neutrophils in IL-1R-deficient mice, numbers of neutrophils in the lung were not reduced by S1P 1 R agonist treatment in IL-1R-deficient mice (Fig. S3H) , suggesting that neutrophil recruitment into the lung requires IL-1R signaling.
Influenza Virus Induced Cytokine Amplification Requires MyD88
Signaling. We next asked how ablating global TLR and IL-1R signaling would affect early innate cytokine production and innate immune cell recruitment following influenza virus challenge. We infected TIR-domain-containing adapter-inducing interferon-β (TRIF) signaling-deficient (Lps2) × MyD88 −/− mice (referred to as dKO hereafter) with influenza virus and treated them with either vehicle of S1P 1 R agonist. The absence of MyD88 and TRIF signaling resulted in significant reduction of IFN-α and multiple cytokines and chemokines following influenza virus infection (Fig. 4A) . Despite a modest inhibition of IFN-α production, treatment of dKO mice with S1P 1 R agonist following influenza virus infection did not result in further significant inhibition of any cytokine or chemokine measured (Fig. 4A) , indicating that MyD88 and TRIF signaling is important for early cytokine amplification and that S1P 1 R agonist suppression of cytokine amplification likely occurs through suppressing one or both of these pathways. S1P 1 R agonist treatment of dKO mice following influenza virus infection resulted in significant inhibition of activated macrophages/monocytes and NK cells in the lung (Fig. 4 B-D) .
To determine whether MyD88, TRIF, or both pathways were necessary for cytokine amplification following influenza virus infection, we infected MyD88 −/− or LPS2 mice separately with influenza virus and measured the production of IFN-α and multiple cytokine and chemokines. We observed significant reductions in IFN-α as well as multiple cytokines and chemokines in MyD88
−/− mice compared with wild-type controls (Fig. 5A) . In contrast to MyD88
−/− mice, we observed no measureable changes in IFN-α or multiple cytokines and chemokines in the BALF of LPS2 compared with wild-type mice following influenza virus infection (Fig. 5A) , indicating that MyD88 signaling, not TRIF, is essential for early cytokine amplification following influenza virus infection.
We next tested whether S1P 1 R agonist therapy suppressed cytokine amplification in MyD88 −/− mice following influenza virus infection. MyD88 −/− mice produced significantly less IFN-α and cytokines and chemokines following influenza challenge compared with MyD88 +/+ controls (Fig. 5B) . Remarkably, S1P 1 R agonist treatment significantly suppressed IFN-α production in MyD88 −/− mice (Fig. 5B, Inset) . We also observed modest but significant reduction in CXCL10 production in S1P 1 R agonist treated compared with vehicle treated MyD88 −/− mice (Fig. 5B ). Despite the low levels of cytokines in vehicle-treated mice, we did not observe significant reductions in IL-6, CCL2, or IFN-γ levels following CYM-5442 treatment in influenza virus-infected MyD88 −/− mice (Fig. 5B) . The numbers of macrophages and neutrophils in the lung following influenza virus infection were significantly reduced in MyD88 −/− compared with MyD88 (Fig. 5C ). Moreover, we observed significant reductions in the frequencies and total numbers of activated macrophages/ monocytes in MyD88 −/− mice (Fig. 5 D and E) . S1P 1 R agonist treatment inhibited the frequency and numbers of activated macrophages in the lung of MyD88 −/− mice, however, did not reduce neutrophil numbers (Fig. 5 D and E) . Taken together, our results suggest that MyD88 signaling is essential for the early amplification of cytokine production in the lung following influenza virus infection.
Discussion
Influenza virus infection of humans is associated with dysregulated and overabundant cytokine/chemokine production and innate inflammatory infiltrates, termed cytokine storm. Earlier we reported, using experimental animal models, that the cytokine storm accompanying H1N1 human pathogenic influenza virus infection was an essential component of the morbidity and mortality observed (6, 7) . We observed that S1P 1 R agonists could blunt influenza virus induced cytokine storm and produce a significantly better clinical outcome than that of an antiviral neuraminidase inhibitor (7) . This report extends these observations by uncovering several unique findings. First, S1P 1 R agonism decreases cytokine storm independently of TLR3 and -7, as well as endosomal or cytosolic signaling pathways. Second, IL-1R signaling is necessary for cytokine amplification and innate immune cell recruitment and activation. Moreover, we identify that IL-1R signaling on nonhematopoietic cells is essential for cytokine amplification. Third, MyD88/TRIF signaling is essential for cytokine amplification and innate immune cell recruitment and activation, with MyD88 being the predominant signaling adaptor with little involvement of TRIF. Moreover, although S1P 1 R agonist treatment likely suppresses the majority of cytokine/chemokine production following influenza infection via targeting MyD88 signaling, S1P 1 R agonist likely also suppresses additional pathways (at or downstream of the IPS-1 adaptor), through as of yet unidentified mechanisms (Fig. S4) . Identification of the mechanism of S1P 1 R agonist-mediated suppression with respect to signaling pathways targeted and the connection with S1P 1 R signaling will be important areas of future investigation.
Poor outcomes following infection with influenza and other respiratory viruses in humans and experimental animals correlate with early dysregulated innate cytokine/chemokine production and immune cell recruitment, collectively called cytokine storm (1, 2, 4, 5, 15, 16 ). Thus, modulating this detrimental immune response via S1P 1 R agonist serves two purposes. First, it is a potential therapeutic strategy to curb morbidity and mortality, and second it is a signaling platform to explore additional checkpoints to further our understanding and designing of novel therapeutic targets to blunt cytokine storm. Because of the redundant signaling pathways that generate innate immune responses, we anticipate effective therapy will require blunting of multiple signaling pathways. Prior studies showed that neutralization of any one inflammatory mediator linked to morbidity and mortality provided little protection to pathogenic influenza virus infection in animal models (14, 17, 18) . The ability of S1P 1 Ragonist treatment to prevent morbidity and mortality in murine and ferret models underscores the utility of S1P 1 R agonists as tools to illuminate signaling pathways that mediate pathology following human pathogenic influenza virus infection and point the way toward therapeutic control of influenza virus-induced immune pathology. Our study emphasizes the redundant sensing of influenza virus by multiple innate signaling pathways. We reveal that S1P 1 R agonist treatment suppresses innate immune cell recruitment and cytokine production independently of multiple innate sensing pathways; thus, our data-together with published reports-strongly suggest that successful modulation of immune pathology during influenza and other respiratory viral infections may require global blunting of innate immune signaling. The fact that MyD88 signaling was responsible for the majority of innate immune cell recruitment and cytokine/chemokine production suggests that therapies that focus to target different components of MyD88 signaling will likely prove successful for therapeutic intervention of influenza virus infection and dissection of signaling pathways necessary for cytokine storm. Our previous work documented a critical role for pulmonary endothelial cells in promoting cytokine amplification and innate immune cell recruitment (6) . The ability of S1P 1 R signaling to globally blunt innate immune responses suggests that S1P 1 R signaling likely targets other cell types in addition to endothelial cells. The identification of MyD88 as an essential signaling pathway required for cytokine amplification is likely to aid in identification of additional pulmonary cell types targeted by S1P 1 R agonist during influenza virus infection. Recent evidence has pointed toward a role for innate immune cell recruitment into the lung as causal to influenza virus induced morbidity and mortality (19, 20) . Importantly, S1P 1 R agonist therapy inhibits both cytokine/chemokine production as well as innate immune cell recruitment.
Aberrant proinflammatory innate immune responses have been implicated in the pathogenesis of multiple viral infections (2, 21), bacterial infections (22) , and autoimmune conditions (23, 24) . A more detailed understanding of the cellular populations and signaling pathways targeted by S1P 1 R-signaling should provide insight into how to temper immune pathology and uncover novel signaling pathways that can be targeted to blunt cytokine storm. This information should point the way toward curbing mortality during respiratory viral infections.
Materials and Methods
Mice, Virus, and Compounds. Six-to 8-wk-old C57BL/6 male mice were bred and maintained in a closed breeding facility at The Scripps Research In- Bone Marrow Chimeras. Femurs were removed from Ly5.2 + IL-1R +/+ and IL-1R −/− mice and the bone marrow was extracted, disrupted through a 100-μm mesh screen, and red blood cells were lysed. Cytokine and Chemokine Analysis. The trachea of killed mice was exposed, transected, and intubated with a blunt 18-gauge needle. One milliliter of PBS supplemented with Complete Mini, EDTA-free Protease Inhibitor Mixture (Roche) was infused and recovered four times. The recovered BALF was spun at 3,000 × g for 3 min at 4°C and stored at −80 0 C until use. Multiplex ELISA was performed on supernatant by Quansys Biosciences to detect TNF-α, MIP-1α, MCP-1, GM-CSF, IFN-γ, and RANTES. ELISAs were also performed using CCL2 (MCP-1), CCL5 (RANTES), CXCL10 (IP-10), IL-6, TNF-α, and IFN-γ Duoset kits (R&D Systems), as well as the VeriKineTM Mouse IFN-Alpha ELISA Kits (R&D Systems).
Cellular Analysis by Flow Cytometry. Lungs were harvested from PBS-perfused mice and mechanically diced into small tissue pieces using surgical scissors. Diced lungs were suspended in 4 mL of CDTI buffer [0.5 mg/mL collagenase from Clostridium histolyticum Type IV (Sigma), 0.1 mg/mL Dnase I from bovine pancreas grade II (Roche), 1 mg/mL Trypsin inhibitor Type Ii-s (Sigma) in DMEM] for 1 h at 37°C. Lung was then disrupted mechanically through a 100-nm filter, and red blood cells were lysed using red blood cell lysis buffer (0.02 Tris·HCL and 0.14 NH 4 Cl). Inflammatory cells were purified by centrifugation in 35% (vol/vol) PBS-buffered Percoll (GE Healthcare Life Sciences) at 500 × g for 15 min. Cell pellets were resuspended in staining buffer and Fc receptors were blocked using 25 μg/mL anti-mouse CD16/32 (BD Biosciences). Cells were stained with the following anti-mouse antibodies: Pacific blue-conjugated CD45.2 (BioLegend; clone 104), PerCP-Cy5.5-conjugated NK1.1 (BD Biosciences; clone PK136), Pacific blue-conjugated B220 (BD Biosciences; clone RA3-6B2), PE-Cy7-conjugated CD11b (eBiosciences; clone M1/70), PerCP-Cy5.5-conjugated CD11c (eBiosciences; clone N418), APC-conjugated Gr-1 (BD Biosciences; clone RB6-8C5), Pacific blueand PE-conjugated Ly6G (BD Biosciences; clone IA8), APC-conjugated F480 (eBioscience; clone BM8), FITC-conjugated CD69 (BD Biosciences; clone H1.2F3). Flow cytometry acquisition was performed with BD FACSDivadriven BD LSR II flow cytometer (Becton, Dickinson). Data were then analyzed with FlowJo software (Treestar).
